High purity exosome standards enhance research reproducibility

Amsbio offers a wide range of highly pure, lyophilized exosome standards designed to support reproducibility and standardization in extracellular vesicle (EV) research.

Exosomes are small lipid nanoparticles actively secreted by exocytosis in most living cells. Regulating pleiotropic physiological and pathological functions – exosomes have been shown to play significant roles in diverse pathological conditions such as cancer, infectious and neurodegenerative diseases. Currently there is growing interest in exosomes as promising new tools for use such as biomarkers and therapeutics.

The importance of reproducibility in extracellular vesicle research is a growing focus worldwide, as reflected in the latest (2023) guidelines from the International Society for Extracellular Vesicles (ISEV). This theme is also explored in a recent blog (see https://www.amsbio.com/news/exosomes_blog) which highlights how exosomes are driving progress in diagnostics and therapeutics

Amsbio exosome standards directly support ISEV priorities, offering high-purity, quality-controlled reference materials to improve comparability across experiments and laboratories.

Derived from a variety of biological sources including cell culture supernatant, human plasma, serum and urine – Amsbio exosomes are purified using a combination of tangential flow filtration (TFF) and size exclusion chromatography (SEC). These isolated high purity exosomes are then quantified and validated for overall protein content, size distribution, concentration and EV specific marker expression.

These exosome standards are lyophilized (freeze-dried) to preserve structural integrity and ensure long-term stability at 4°C for up to 36 months. The rigorous quality control and high purity of Amsbio exosome standards both enhance experimental reproducibility and facilitates result comparison between different research groups.

Quick and easy to reconstitute, exosome standards serve as positive controls for applications including marker assessment, extracellular vesicle (EV) quantification, flow cytometry, immunocapture performance evaluation and OMICS analysis. AMSBIO also offers fluorescent labelling for all exosome standards.

For further information on how exosome standards can improve reproducibility in your EV research,please visit https://www.amsbio.com/research-areas/exosomes/exosomes-standards or contact Amsbio on +31-72-8080244 / +44-1235-828200 / +1-617-945-5033 / [email protected].

Now part of the Europa Biosite group of companies, AMS Biotechnology (Amsbio) is recognized as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products, and services for R&D in the medical, nutrition, cosmetics, and energy industries. Amsbio has in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion, and proliferation. This expertise in cell culture and the ECM allows Amsbio to partner with clients in tailoring cell systems to enhance organoid and spheroid screening outcomes using a variety of 3D culture systems, including organ-on-a-chip microfluidics. For drug discovery research, Amsbio offers assays, recombinant proteins, and cell lines. Drawing upon a huge and comprehensive biorepository, Amsbio is widely recognized as a leading provider of high-quality tissue specimens (including custom procurement) from both human and animal tissues. The company provides unique clinical grade products for stem cells and cell therapy applications. This includes GMP cryopreservation technology, and high-quality solutions for viral delivery.